Morgan Stanley Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $573
Morgan Stanley analyst Erin Wright maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $603 to $573.
Related Posts
BeiGene’s Poster For Upcoming Conference Reveals Promising Lung Cancer Data
BeiGene Ltd's (NASDAQ: BGNE) Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR)
A Look Into Technology Sector Value Stocks
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices…
Atara Lays Off 20% Of Its Workforce, Issues Update On Cell Therapies
Atara Biotherapeutics Inc (NASDAQ:ATRA) will reduce cash burn by laying off 20% of its staff and extend the cash…